Edition:
United States

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

4.77USD
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
$4.77
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
91,058
52-wk High
$15.20
52-wk Low
$4.39

Latest Key Developments (Source: Significant Developments)

Syndax To Host Conference Call To Provide Update On The Phase 3 Breast Cancer Trial (E2112)
Thursday, 25 Oct 2018 04:05pm EDT 

Oct 25 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX TO HOST CONFERENCE CALL TO PROVIDE UPDATE ON THE PHASE 3 BREAST CANCER TRIAL (E2112) AND TO ANNOUNCE ITS REGISTRATION TRIAL OF ENTINOSTAT WITH KEYTRUDA IN PD-(L)1 REFRACTORY NON-SMALL CELL LUNG CANCER.- ENROLLMENT COMPLETED IN E2112; PFS NOT STATISTICALLY SIGNIFICANT.TRIAL CONTINUES AS PLANNED HAVING PASSED 3RD INTERIM ANALYSIS FOR OS WITH ADDITIONAL PLANNED OS ANALYSES EVERY 6 MONTHS.PLANS TO INITIATE RANDOMIZED REGISTRATION ENABLING TRIAL COMPARING ENTINOSTAT-KEYTRUDA COMBINATION TO STANDARD OF CARE CHEMOTHERAPY.ANTICIPATES BEGINNING COMPARING ENTINOSTAT-KEYTRUDA COMBINATION TO STANDARD OF CARE CHEMOTHERAPY TRIAL IN H1 2019.ANTICIPATES TOP-LINE DATA FROM TRIAL COMPARING ENTINOSTAT-KEYTRUDA COMBINATION TO STANDARD OF CARE CHEMOTHERAPY IN H2 2020.  Full Article

Syndax Pharmaceuticals Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 04:05pm EDT 

Aug 7 (Reuters) - Syndax Pharmaceuticals Inc ::PHASE 1 TRIAL OF SNDX-6352 IN CHRONIC GRAFT VERSUS HOST DISEASE EXPECTED TO COMMENCE BY END OF YEAR.PFS RESULTS FROM PIVOTAL PHASE 3 E2112 TRIAL OF ENTINOSTAT PLUS EXEMESTANE IN HR+, HER2- BREAST CANCER EXPECTED IN 3Q18.SYNDAX PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.74.Q2 EARNINGS PER SHARE VIEW $-0.87 -- THOMSON REUTERS I/B/E/S.SYNDAX PHARMACEUTICALS - FOR Q3 & FULL YEAR 2018, RESEARCH AND DEVELOPMENT EXPENSES ARE EXPECTED TO BE $14 TO $16 MILLION AND $59 TO $62 MILLION, RESPECTIVELY.  Full Article

Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
Wednesday, 30 May 2018 04:05pm EDT 

May 30 (Reuters) - Nektar Therapeutics ::SYNDAX AND NEKTAR THERAPEUTICS ANNOUNCE IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION.NEKTAR- ANNOUNCED NON-EXCLUSIVE, CLINICAL COLLABORATION TO EVALUATE SAFETY, EFFICACY OF NEKTAR'S NKTR-214, IN COMBINATION WITH SYNDAX'S ENTINOSTAT.NEKTAR THERAPEUTICS - COLLABORATION WILL EVALUATE COMBINATION OF ENTINOSTAT WITH NKTR-214 IN PATIENTS WITH PD-1 REFRACTORY MELANOMA.NEKTAR THERAPEUTICS - ADDITIONAL FINANCIAL DETAILS AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED.  Full Article

Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer
Wednesday, 10 Jan 2018 07:00am EST 

Jan 10 (Reuters) - Syndax Pharmaceuticals Inc ::SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER.SYNDAX PHARMACEUTICALS INC - NEW CLINICAL COLLABORATION WITH GENENTECH, A MEMBER OF ROCHE GROUP.SYNDAX PHARMACEUTICALS - COS WILL EVALUATE COMBINATION OF CO'S ENTINOSTAT AND GENENTECH'S ATEZOLIZUMAB.SYNDAX PHARMACEUTICALS INC - FINANCIAL AND OTHER TERMS OF AGREEMENT WERE NOT DISCLOSED..SYNDAX PHARMACEUTICALS INC - GENENTECH WILL BE RESPONSIBLE FOR CONDUCTING TRIAL.SYNDAX PHARMACEUTICALS INC - TRIAL WILL BE CONDUCTED AS PART OF MORPHEUS, ROCHE'S NOVEL CANCER IMMUNOTHERAPY DEVELOPMENT PLATFORM.  Full Article

Syndax Pharmaceuticals reports Q3 loss per share $0.68
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update.Q3 loss per share $0.68.Q3 earnings per share view $-0.80 -- Thomson Reuters I/B/E/S.  Full Article

Syndax Pharma enters into license agreement with unit of Allergan
Tuesday, 17 Oct 2017 07:53am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals :On Oct 13, co entered into license agreement with Vitae Pharmaceuticals, a subsidiary of Allergan Plc​ - SEC filing.Pursuant to agreement, co will make an upfront payment of $5.0 million to Allergan​.If parties commercialize Menin assets, co obligated to pay Allergan low single to low double-digit royalties on sales​.Under agreement, Allergan grants co worldwide license to portfolio of orally-available small molecule inhibitors of interaction of MLL protein​.Under agreement, may have to pay allergan up to $99 million in one-time development, regulatory milestone payments subject to achievement of milestones.In event of commercializing Menin assets, co to also pay up to $70 million in potential one-time sales-based milestone payments​.Company will be solely responsible for development and commercialization of Menin assets​.Under certain circumstances, co may be required to share a percentage of non-royalty income from sublicensees, with Allergan​.  Full Article

Syndax Pharmaceuticals says ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​
Tuesday, 17 Oct 2017 07:00am EDT 

Oct 17 (Reuters) - Syndax Pharmaceuticals Inc ::Syndax Pharmaceuticals Inc - ‍expands pipeline with exclusive worldwide license to Allergan's portfolio of Menin-MLL inhibitors​.Syndax Pharmaceuticals Inc - ‍ entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, inc., a subsidiary of Allergan PLC​.  Full Article